The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
Open accessAbstract
UNLABELLED: The integrin alpha v beta3 receptor is upregulated on tumor cells and endothelium and plays important roles in angiogenesis and metastasis. Arg-Gly-Asp (RGD) peptide ligands have high affinity for these integrins and can be radiolabeled for PET imaging of angiogenesis or tumor development. We have assessed the safety, stability, and tumor distribution kinetics of a novel radiolabeled RGD-based integrin peptide-polymer conjugate, 18F-AH111585, and its feasibility to detect tumors in metastatic breast cancer patients using PET. METHODS: The biodistribution of 18F-AH111585 was assessed in 18 tumor lesions from 7 patients with metastatic breast cancer by PET, and the PET data were compared with CT results. The metabolic stability of 18F-AH111585 was assessed by chromatography of plasma samples. Regions of interest (ROIs) defined over tumor and normal tissues of the PET images were used to determine the kinetics of radioligand binding in tissues. RESULTS: The radiopharmaceutical and PET procedures were well tolerated in all patients. All 18 tumors detected by CT were visible on the 18F-AH111585 PET images, either as distinct increases in uptake compared with the surrounding normal tissue or, in the case of liver metastases, as regions of deficit uptake because of the high background activity in normal liver tissue. 18F-AH111585 was either homogeneously distributed in the tumors or appeared within the tumor rim, consistent with the pattern of viable peripheral tumor and central necrosis often seen in association with angiogenesis. Increased uptake compared with background (P = 0.002) was demonstrated in metastases in lung, pleura, bone, lymph node, and primary tumor. CONCLUSION: 18F-AH111585 designed to bind the alpha v beta3 integrin is safe, metabolically stable, and retained in tumor tissues and detects breast cancer lesions by PET in most anatomic sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., & Gasparini, G. (1992) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1875 · Cited by 1,775
Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., & Buck, C. A. (1990) · PubMed · Cited by 760
αv Integrins as receptors for tumor targeting by circulating ligands
Pasqualini, R., Koivunen, E., & Ruoslahti, E. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-542 · Cited by 744
Spectral Analysis of Dynamic PET Studies
Cunningham, V. J., & Jones, T. (1993) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1993.5 · Cited by 498
Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.-F., Goebel, M., Hein, R., Wester, H.-J., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020070 · Cited by 489
Koivunen, E., Wang, B., & Ruoslahti, E. (1995) · Nature Biotechnology · doi:10.1038/nbt0395-265 · Cited by 477
Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C., & Harris, A. L. (1995) · The Journal of Pathology · doi:10.1002/path.1711770310 · Cited by 436
Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch–Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 381
αvβ3 and αvβ5 Integrin Expression in Glioma Periphery
Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R. S., Nikas, D. C., Strasser, J. F., Villani, R., Cheresh, D. A., & Black, P. M. (2001) · Neurosurgery · doi:10.1097/00006123-200108000-00022 · Cited by 341
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., Schnell, O., Niemeyer, M., Kessler, H., Wester, H.-J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0266 · Cited by 330
Imaging Angiogenesis: Applications and Potential for Drug Development
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., & Thrall, J. H. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji023 · Cited by 325
Wu, Y., Zhang, X., Xiong, Z., Cheng, Z., Fisher, D. R., Liu, S., Gambhir, S. S., & Chen, X. S. (2005) · PubMed · Cited by 325
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.
Gasparini, G., Brooks, P. C., Biganzoli, E. M., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R., & Cheresh, D. A. (1998) · PubMed · Cited by 280
Zitzmann, S., Ehemann, V., & Schwab, M. (2002) · PubMed · Cited by 265
Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone
Pecheur, I., Peyruchaud, O., Serre, C., Guglielmi, J., Voland, C., Bourre, F., Margue, C., Cohen‐Solal, M., Buffet, A., Kieffer, N., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0911fje · Cited by 223
Beer, A. J., Grosu, A.-L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Wester, H.-J., Haubner, R., & Schwaiger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0528 · Cited by 217
Stessels, F., Van den Eynden, G., Van der Auwera, I., Salgado, R., Van den Heuvel, E., Harris, A. L., Jackson, D. G., Colpaert, C. G., Van Marck, E. A., Dirix, L. Y., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601727 · Cited by 214
Role of integrins in angiogenesis
Brooks, P. C. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00381-4 · Cited by 193
Beer, A. J., Haubner, R., Wolf, I., Goebel, M., Luderschmidt, S., Niemeyer, M., Grosu, A., Martínez, M.-J., Wester, H. J., Weber, W., et al. (2006) · PubMed · Cited by 144
Liu, S., Hsieh, W., Jiang, Y., Kim, Y., Sreerama, S. G., Chen, X. S., Jia, B., & Wang, F. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603081 · Cited by 143
Cancer vascularization: implications in radiotherapy?
Koukourakis, M. I., Giatromanolaki, A. N., Sivridis, E., & Fezoulidis, I. V. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00677-5 · Cited by 104
Molecular targeting with peptides or peptide-polymer conjugates: just a question of size?
Wester, H., & Kessler, H. (2005) · PubMed · Cited by 102
Multimodality Tumor Imaging Targeting Integrin α v β 3
Cai, W., Gambhir, S. S., & Chen, X. S. (2005) · BioTechniques · doi:10.2144/000112091 · Cited by 65
Cited by
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Kapp, T. G., Rechenmacher, F., Neubauer, S., Maltsev, O. V., Cavalcanti-Adam, E. A., Zarka, R., Reuning, U., Notni, J., Wester, H.-J., Mas-Moruno, C., et al. (2017) · Scientific Reports · doi:10.1038/srep39805 · Cited by 620
Integrins as therapeutic targets: lessons and opportunities
Cox, D., Brennan, M., & Moran, N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3266 · Cited by 456
Liu, S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900167c · Cited by 344
Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis
Lee, S., Xie, J., & Chen, X. (2010) · Chemical Reviews · doi:10.1021/cr900361p · Cited by 324
Metadata
- Authors
- Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland, B., Cohen, P. S., Hui, A.-M., Palmieri, C., Osman, S., Glaser, M., Turton, D., Al-Nahhas, A., & Aboagye, E. O.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2008-05-15
- Volume
- 49
- Issue
- 6
- Pages
- 879-886
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2101281436
- Cited by
- 280
- References
- 26
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.